论文部分内容阅读
目的探讨奥扎格雷钠阿司匹林联合治疗急性脑梗死的疗效及其作用机制。方法选取2010年1月—2012年12月郑州市第二人民医院确诊的急性脑梗死患者138例,随机分为治疗组和对照组各69例,两组均予脱水、降颅压、改善脑循环等常规药物治疗。对照组给予阿司匹林肠溶片口服;治疗组在对照组的基础上给予奥扎格雷钠静脉中滴注。均持续14d为1个疗程。1个疗程后比较两组疗效。结果治疗组患者总有效率为92.8%明显高于对照组的75.0%(P<0.05);治疗组的NIHSS及ADL评分均明显优于对照组(P均<0.05)。两组均表现出良好耐受性,未发现明显不良反应。结论应用奥扎格雷钠阿司匹林联合治疗急性脑梗死能明显改善患者神经功能缺损症状,优于阿司匹林单药治疗,且毒副作用少,值得推广。
Objective To investigate the efficacy and mechanism of ozagrel sodium aspirin in the treatment of acute cerebral infarction. Methods A total of 138 patients with acute cerebral infarction confirmed by the Second People’s Hospital of Zhengzhou City from January 2010 to December 2012 were randomly divided into treatment group (69 cases) and control group (69 cases). Both groups were given dehydration, intracranial pressure reduction, Circulation and other conventional drug treatment. The control group was given aspirin enteric-coated tablets orally; the treatment group was given intraocular infusion of ozagrel sodium on the basis of the control group. All 14d for a course of treatment. After a course of treatment, the two groups were compared. Results The total effective rate of the treatment group was 92.8%, which was significantly higher than that of the control group (75.0%, P <0.05). NIHSS and ADL scores of the treatment group were significantly better than those of the control group (all P <0.05). Both groups showed good tolerability and no significant adverse reactions were found. Conclusion The combination of ozagrel sodium and aspirin in the treatment of acute cerebral infarction can significantly improve the symptoms of patients with neurological deficits, superior to aspirin monotherapy, and less side effects, it is worth promoting.